Skip To Main Content
Astrid Blicher Schelde on Muck Rack

Astrid Blicher Schelde

As seen in: PLOS Medicine, Journal of Clinical Epidemiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Astrid Blicher

Contact Astrid Blicher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study

|
By Katrine Finderup Nielsen, Statens Serum Institut, Ida Rask Moustsen-Helms, Astrid Blicher Schelde
| PLOS Medicine Verified
SARS-CoV-2 reinfection During the Alpha period, 437 individuals had a confirmed SARS-CoV-2 reinfection (Table 2). The adjusted VE against reinfection was not statistically significant (−55%, 95% confidence interval (CI): -Inf to 100%) 14 to 43 days after vaccination, but rose to 69% (95% CI: -Inf to 100%) 44 to 103 days after vaccination and 71% (95% CI: -Inf to 100%) 104 days or more after vaccination (Fig 1, Table 2).
Open in Who Shared Issue with article?

Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

|
By Mie Agermose Gram, Statens Serum Institut, Hanne-Dorthe Emborg, Astrid Blicher Schelde
| PLOS Medicine Verified
Statistical analysis Characteristics of the study population were described using proportions and stratified by vaccination status. Time until SARS-CoV-2 infection (both asymptomatic and symptomatic) or COVID-19 hospitalization was analyzed in 3 periods where the relevant variant accounted for at least 75% of all WGS RT-PCR confirmed cases: Alpha (February 20 to June 15, 2021), Delta (July 4 to November 20, 2021), and Omicron (December 21, 2021 to January 31, 2022) (Fig 1). Fig 1.
Open in Who Shared Issue with article?

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

|
By Christian Hansen, Astrid Blicher Schelde, Ida Rask Moustsen-Helm, Hanne-Dorthe Emborg
| medRxiv
ABSTRACT In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines.
Open in Who Shared Issue with article?
See all 8 licensed articles (10 Total)